Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -86.96% | -56.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -86.96% | -56.98% | |||
| Cost of Revenue | -449.43% | -10.90% | |||
| Gross Profit | 584.10% | -47.80% | |||
| SG&A Expenses | 277.38% | 2.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 164.01% | -4.24% | |||
| Operating Income | -200.42% | -16.49% | |||
| Income Before Tax | -136.29% | -19.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -136.29% | -19.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -136.29% | -19.79% | |||
| EBIT | -200.42% | -16.49% | |||
| EBITDA | -201.25% | -16.55% | |||
| EPS Basic | -137.50% | -20.00% | |||
| Normalized Basic EPS | -191.67% | -9.09% | |||
| EPS Diluted | -137.50% | -20.00% | |||
| Normalized Diluted EPS | -191.67% | -9.09% | |||
| Average Basic Shares Outstanding | 0.09% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||